OT ALERT HALO !!!
I guess it is time to talk
HALO. The stock had a great day after the company cleared the air on its
PegPh20 program. Prior to the official halt of the Phase II program back in April, the media, analysts and investors were rallying the stock to its 52-week high of $ 18,00/shr plus on the back of PegPh20. When the FDA halted the program at the suggestion of an independent group who looked at the early data, there came into question whether PegPh20 was going to be an effective product against Pancreatic Cancer (PC) as it was determined that a higher number than expected patients enrolled in the Phase II program were susceptible to thrombosis. If this were the case, the Phase II study might have to be called off. So even though HALO had other irons in the healthcare fire (Enhanze), clearly the general market wasn't prepared to support the stock without PegPh20 headlining it.
Fast forward to today, we heard today that the 202 study has produced some amazing results, the PegPh20 combo with major cancer drugs is in fact the best combination attack on PC. PegPh20 is delivering a safe, effective treatment for patients with high levels of hyaluronan, at a level that is more than twice as effective as Abraxane (No. 1 drug used today), i.e., the patient is living more than twice as long with PegPh20 formulation. So now we know that the leading product for HALO is also the best product in the world to reduce death times in PC patients with high HA.
I could go on for hours on how this effects the prospects for HALO but I'll stop here by saying that the march to $ 18.00/shr can resume, in fact, the company is far better off than it was when it made its last march to $ 18.00/shr. They are looking for a registration of a specific high HA group to fast-track PegPh20 and they will approach the FDA for this ASAP with the data they have now; demonstrating many deaths being prolonged. They are racing to get two studies for Non Small Cell Lung Cancer in trial studies (one has started) and they are looking at Gastric/Intestinal Cancer for early 2016.
All of this decisive news came from the data of 202. On Monday, we'll hear about that important Phase IB study and that could be ground breaking as well. So we went from not knowing if PEgPh20 would be coming back again, for significant trials, to knowing it is the best solution for some cancers in the world today! Not bad. The stock has 20 MM shares short, sorry to say this but they are all screwed, the stock will now go higher until they are out of the system, not unlike TSLA. The analysts will have to look at the data before they can give their assessment, but HALO's aggressive $ 145 MM budget for PegPh20 this year speaks volumes on its own. The new CMO (Chief Medical Officer) is nothing short of brilliant, she gives some colour to where we sees HALO going this year and she is well researched with this company already. You can see the stock is up in AH and here is a copy of their itinerary for 2015:
Attachment 325957
Enjoy the rally, the company is back, the biotech sector is number one right now and you own the best of the best in cancer therapy!
Some reading: http://www.reuters.com/article/2015/...0KG2CO20150107